#Primary Antibodies market | Explore Tumblr posts and blogs

harshnews · 3 months ago

Text

Primary Antibodies Market Size, Share, Trends, Opportunities, Key Drivers and Growth Prospectus

"Global Primary Antibodies Market – Industry Trends and Forecast to 2028

Global Primary Antibodies Market, By Type (Monoclonal Antibodies, Polyclonal Antibodies), Technology (Immunohistochemistry, Immunofluorescence, Western Blotting, Flow Cytometry, Immunoprecipitation, ELISA, Other Technologies), Source (Mouse, Rabbit, Goat, Other Sources), Research Area (Infectious Diseases, Immunology, Oncology, Stem Cells, Neurobiology, Others), Application (Proteomics, Drug Development, Genomics), End User (Pharmaceutical and Biotechnological Companies, Academic and Research Institutes, Contract Research Organizations), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Access Full 350 Pages PDF Report @

**Segments**

- Type: The primary antibodies market can be segmented based on type into monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are derived from a single parent cell, resulting in high specificity and consistency, while polyclonal antibodies are produced by multiple parent cells, offering a broader range of targets. - Application: The market can also be segmented according to application, including research applications, clinical diagnostics, and therapeutics. Research applications account for a significant portion of the market, driven by ongoing advancements in biotechnology and life sciences research. - End-user: End-user segmentation of the primary antibodies market includes academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations. Academic and research institutes are major consumers of primary antibodies for various research purposes.

**Market Players**

- Thermo Fisher Scientific Inc.: Known for its comprehensive range of primary antibodies, Thermo Fisher Scientific offers high-quality products for various research and diagnostic applications. - Abcam plc: Abcam is a prominent player in the primary antibodies market, offering a wide selection of validated antibodies for research purposes. - Merck KGaA: Merck KGaA provides primary antibodies through its life science division, catering to the needs of researchers and clinicians worldwide. - F. Hoffmann-La Roche Ltd: As a leading pharmaceutical company, Roche offers a diverse portfolio of primary antibodies for use in diagnostics and research. - Bio-Rad Laboratories, Inc.: Bio-Rad Laboratories is a key player in the market, offering primary antibodies that are widely used in research laboratories and clinical settings.

The global primary antibodies market is characterized by the presence of several established players who compete based on product quality, innovation, and strategic partnerships. These companies invest significantly in research and development to introduce new and improved primary antibodies, catering to the evolving needs of the healthcare and life sciences industries.

https://www.databridgemarketresearch.com/reports/global-primary-antibodies-marketThe primary antibodies market is a dynamic and rapidly evolving sector that plays a crucial role in various applications such as research, clinical diagnostics, and therapeutics. The segmentation of the market based on type into monoclonal antibodies and polyclonal antibodies highlights the diverse offerings in terms of specificity and target range. Monoclonal antibodies, derived from a single parent cell, provide high specificity and consistency, making them ideal for targeted applications. On the other hand, polyclonal antibodies offer a broader range of targets due to their production from multiple parent cells. This variety in antibody types caters to the specific needs of researchers and clinicians in different fields.

When considering the market segmentation based on application, it is evident that research applications hold a significant share of the primary antibodies market. The continuous advancements in biotechnology and life sciences research drive the demand for primary antibodies in research settings. Clinical diagnostics and therapeutics also play vital roles in driving the market, showcasing the versatility of primary antibodies across different sectors. The diverse applications of primary antibodies indicate the widespread adoption and utilization of these products in various industries.

End-user segmentation further enhances the understanding of the primary antibodies market by highlighting the different consumer groups. Academic and research institutes stand out as major end-users, utilizing primary antibodies for a wide range of research purposes. Pharmaceutical and biotechnology companies, as well as contract research organizations, also contribute significantly to the demand for primary antibodies. The diverse end-user base reflects the widespread use of primary antibodies across different sectors and underlines the importance of these products in advancing scientific research and diagnostics.

Market players such as Thermo Fisher Scientific Inc., Abcam plc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories, Inc. are key contributors to the global primary antibodies market. These companies are known for their extensive product offerings, quality assurance, and commitment to innovation. By investing in research and development, these market players continue to introduce new and improved primary antibodies that align with the evolving needs**Segments:** - Type: The primary antibodies market can be segmented into monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies offer high specificity and consistency, while polyclonal antibodies provide a broader range of targets. - Application: Segmentation based on application includes research, clinical diagnostics, and therapeutics. Research applications dominate the market driven by advancements in biotechnology. - End-user: End-user segmentation comprises academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations.

The global primary antibodies market, segmented by type, application, and end-user, is a dynamic sector with significant contributions from established players such as Thermo Fisher Scientific Inc., Abcam plc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories, Inc. These companies compete based on product quality, innovation, and strategic partnerships, driving growth and development in the market. The market's segmentation enables a deeper understanding of the diverse offerings of monoclonal and polyclonal antibodies, catering to the evolving needs of researchers and clinicians across various industries.

The application segment showcases the market's versatility, with research applications holding a substantial share due to ongoing advancements in biotechnology and life sciences research. Clinical diagnostics and therapeutics also play crucial roles, underlining the widespread adoption of primary antibodies in diverse sectors. Additionally, end-user segmentation sheds light on the varied consumer groups, with academic and research institutes emerging as significant users of primary antibodies for research purposes. Pharmaceutical

The Primary Antibodies Market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance.

Major Points Covered in TOC:

Primary Antibodies Market Overview: It incorporates six sections, research scope, significant makers covered, market fragments by type, Primary Antibodies Market portions by application, study goals, and years considered.

Primary Antibodies Market Landscape: Here, the opposition in the Worldwide Primary Antibodies Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances Landscape, and most recent patterns, consolidation, development, obtaining, and portions of the overall industry of top organizations.

Primary Antibodies Profiles of Manufacturers: Here, driving players of the worldwide Primary Antibodies Market are considered dependent on deals region, key items, net edge, income, cost, and creation.

Primary Antibodies Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income, creation, portion of the overall industry, CAGR, and market size by locale. Here, the worldwide Primary Antibodies Market is profoundly examined based on areas and nations like North America, Europe, China, India, Japan, and the MEA.

Primary Antibodies Application or End User: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide Primary Antibodies Market.

Primary Antibodies Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge, and creation and creation esteem estimate by type.

Keyword: Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.

The Report Can Answer the Following Questions:

Who are the global key players of Primary Antibodies industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What are the types and applications of Primary Antibodies? What is the market share of each type and application?

What are the upstream raw materials and manufacturing equipment of Primary Antibodies? What is the manufacturing process of Primary Antibodies?

Economic impact on Primary Antibodies industry and development trend of Primary Antibodies industry.

What are the key factors driving the global Primary Antibodies industry?

What are the key market trends impacting the growth of the Primary Antibodies market?

What are the Primary Antibodies market challenges to market growth?

What are the Primary Antibodies market opportunities and threats faced by the vendors in the global Primary Antibodies market?

Browse Trending Reports:

6g Substrate Materials Market Cloud Application Programming Interface Api And Management Platforms And Middleware Market Abscisic Acid Aba Market Benign Mesonephroma Market Cancer Supportive Care Products Market Data Center Interconnect Market Potash Fertilizers Market Private Label Food And Beverage Market Relational Database Market Commercial Lighting Market Ethoxylates Market Eclinical Solutions Market Vaccines Market Spark Plug Market High Visibility Clothing Market Gas Turbine Services Market Dessert Mix Market Lipid Nutrition Market Barrier Films Flexible Electronics Market Nasal Polyposis Drugs Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: [email protected]"

#Primary Antibodies Market

0 notes

palashbhagat5 · 1 hour ago

Text

0 notes

digitalmore · 1 day ago

Text

#IFTTT #DigitalMore.co

0 notes

credenceresearchdotblog · 4 days ago

Text

The Glioblastoma Treatment Drugs Market is projected to grow from USD 2665 million in 2024 to an estimated USD 5589.2 million by 2032, with a compound annual growth rate (CAGR) of 9.7% from 2024 to 2032. Glioblastoma multiforme (GBM) is the most aggressive and common type of primary brain tumor in adults. Known for its rapid progression and resistance to standard therapies, GBM presents a significant challenge to healthcare professionals and researchers worldwide. The growing prevalence of glioblastoma, coupled with advancements in oncology, has spurred significant developments in the glioblastoma treatment drugs market.

Browse the full report at https://www.credenceresearch.com/report/glioblastoma-treatment-drugs-market

Market Overview

The glioblastoma treatment drugs market is experiencing steady growth, driven by the increasing incidence of GBM and rising investments in cancer research. According to recent statistics, the global glioblastoma treatment market was valued at approximately USD 2.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 8% during the forecast period of 2023–2030.

Current Treatment Options

The primary treatment for glioblastoma typically involves surgical resection, followed by radiation therapy and chemotherapy. Temozolomide (TMZ), an oral alkylating agent, remains the gold standard chemotherapy drug for GBM treatment. However, the recurrence of glioblastoma post-treatment remains a critical concern.

To address these challenges, several new drugs and therapeutic approaches are entering the market, including:

Targeted Therapies Drugs targeting specific molecular pathways, such as EGFR (epidermal growth factor receptor) inhibitors, have shown promise. Agents like bevacizumab, an anti-VEGF (vascular endothelial growth factor) monoclonal antibody, are being used to control tumor angiogenesis and prolong progression-free survival.

Immunotherapies Immunotherapy has emerged as a game-changer in oncology. Immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies are being explored to harness the body’s immune system to fight glioblastoma. Clinical trials of drugs like nivolumab are underway, aiming to improve patient outcomes.

Gene and Cell-Based Therapies Advances in gene editing and cell-based therapies have paved the way for personalized medicine in glioblastoma treatment. Oncolytic viral therapies, which use genetically modified viruses to target cancer cells, are gaining traction in research and development pipelines.

Challenges in the Market

Despite significant progress, the glioblastoma treatment drugs market faces several hurdles:

High Costs: Advanced therapies often come with a hefty price tag, limiting access for many patients.

Complex Biology of GBM: The heterogeneity and adaptability of glioblastoma tumors make them highly resistant to treatment.

Regulatory Barriers: Stringent approval processes for new drugs can delay market entry.

Future Outlook

The future of the glioblastoma treatment drugs market looks promising, driven by ongoing research and technological advancements. The integration of artificial intelligence and big data analytics in drug discovery is expected to expedite the development of effective treatments. Additionally, combination therapies that incorporate multiple approaches—such as chemotherapy, immunotherapy, and gene therapy—are likely to emerge as the new standard of care.

Government initiatives to support cancer research and increasing funding from private organizations further bolster the market’s growth potential. However, addressing the affordability and accessibility of these advanced treatments remains crucial to ensuring better outcomes for patients worldwide.

Key Player Analysis:

Amgen, Inc.

Amneal Pharmaceuticals

Arbor Pharmaceuticals, LLC

AstraZeneca PLC

Hoffmann-La Roche Ltd.

Gene Therapy

GlaxoSmithKline plc (GSK)

Glioma Steam Cell Targeting

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kinase Inhibitor

Merck & Co., Inc.

MiRNA Targeting

Novartis AG

Pfizer Inc.

Roche Holding AG

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Segmentation:

By Treatment

Surgery

Radiation Therapy

Chemotherapy

Targeted Therapy

Tumor Treating Field (TTF) Therapy

Immunotherapy

By Drug Class:

Antineoplastic

VEGF/VEGFR Inhibitors

Alkylating Agents

Miscellaneous Antineoplastic

By Distribution Channel:

Hospitals

Cancer Research Organizations

Long Term Care Centers

Diagnostic Centers

By Region:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/glioblastoma-treatment-drugs-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

0 notes

deshpandeisha · 5 days ago

Text

Introduction to Monoclonal Antibodies: Basics and Mechanisms of Action

The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast period. Rising adoption in personalized medicine and precision therapies, expanding regulatory approvals of monoclonal antibodies by regulatory agencies across the globe, and increasing technological advancements in biotechnology and immunology are some of the factors expected to drive market revenue growth.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/2533

Competitive Terrain:

The global Monoclonal Antibodies industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc.; Bayer AG; Bristol Myers Squibb; F. Hoffman-La Roche Ltd.; Viatris Inc.; Biogen Inc.; Thermo Fisher Scientific, Inc.; Novo Nordisk A/S; Sanofi S.A., and Teva Pharmaceutical Industries Ltd

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Monoclonal Antibodies market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Monoclonal Antibodies market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Monoclonal Antibodies market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/2533

Market Segmentations of the Monoclonal Antibodies Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Monoclonal Antibodies market on the basis of product, application, and region:

Segments Covered in this report are:

Source Outlook (Revenue, USD Billion; 2019-2032)

Humanized mAb

Human mAb

Murine mAb

Chimeric mAb

Indication Outlook (Revenue, USD Billion; 2019-2032)

Cancer

Breast cancer

Colorectal cancer

Lung cancer

Ovarian cancer

Others

Autoimmune Diseases

Inflammatory Diseases

Infectious Diseases

Others

Production Type Outlook (Revenue, USD Billion; 2019-2032)

In Vivo

In Vitro

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/monoclonal-antibodies-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/2533

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report: Ceramic Tiles Market | Life Science Analytics Market

0 notes

healthcaremarketanalysis · 9 days ago

Text

mRNA Synthesis & Manufacturing Market worth $738.3 million by 2029

The mRNA synthesis and manufacturing market is projected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024. This market is projected to grow at a CAGR of 3.4% over the forecast period. The primary drivers behind the expansion of this industry are the Growing focus on mRNA-based vaccine development, expanding therapeutic applications of mRNA technology, advancements in mRNA synthesis technology, increased outsourcing for mRNA synthesis and modification, and collaborations among industry players. However, stability, storage, and manufacturing scalability present a challenge to this industry. This is further amplified by the slow patient adoption rate and the complexity of the development of mRNA-based therapy.

In many important respects, artificial intelligence (AI) is transforming the mRNA synthesis and manufacturing sector. First, by scanning large databases to find suitable mRNA sequences for therapeutic usage, artificial intelligence speeds up drug research and development greatly. Developed tools like the LinearDesign AI aim to maximize mRNA sequences, therefore producing vaccines with more antibody responses than conventional techniques. From raw material acquisition to final product packaging, artificial intelligence maximizes several manufacturing steps, thereby lowering costs and raising efficiency. AI-powered predictive maintenance reduces downtime and guarantees manufacturing equipment's seamless running.

Download PDF Brochure:

Browse in-depth TOC on "mRNA Synthesis & Manufacturing Market"

250 - Tables

50 - Figures

250 - Pages

The market is expanding rapidly due to factors such as the development of mRNA-based vaccines and expanded applications such as cancer immunotherapies. Furthermore, improvements in mRNA synthesis technology, a rise in mRNA synthesis and modification outsourcing, and industry players working together to create mRNA therapies all contribute to the growth of the mRNA synthesis and manufacturing market. Additionally, factors such as advancements in drug delivery technologies, growth in the regenerative medicines market, and increasing government funding and private investments in the mRNA therapeutics market will further provide revenue growth opportunities for the players operating in mRNA synthesis & manufacturing.

Based on product type, the mRNA synthesis and manufacturing products market is divided into two broad categories, consumables and instruments. The consumables segment of the market held the largest market share in 2023, due to the sustained use of consumables such as nucleotides, RNA polymerase, reverse transcriptase, buffer, and reagents that also require frequent repurchases. The consumables segment will be experiencing high growth due to several factors, including an increase in the mRNA therapeutics pipeline and growing investments made to develop mRNA-based therapeutics, advancement in mRNA synthesis technologies, increase in demand for consumables among contract service providers with the growing trend of outsourcing.

Based on service type, the global mRNA synthesis and manufacturing services market has been categorized into four service types: mRNA synthesis, modification, and related activities; purification of mRNA; analytical and characterization services; and scale-up and manufacture activities. In 2023, the mRNA synthesis and modification services captured the highest market share because of the demand for custom and modified mRNA sequences, which are intended to enhance therapeutic candidates for the molecules market. Given the expanding uses of the mRNA technology, researchers and developers are looking for mRNA sequences that can incorporate protein expression enhancement or immune response improvement.

Based on application, the market for mRNA synthesis and manufacturing has been divided into segments including vaccines and cell & gene therapy. The vaccine segment has the dominant share in the market in 2023. The large share of this segment can be supported by the large number of clinical trials of mRNA vaccines for various diseases infectious diseases, cancer and rare genetic disorders. The remarkable success of mRNA-based COVID-19 vaccines has not only proven the efficacy & scalability of mRNA technology but also catalysed interest in targeting other therapy areas, such as cancer and rare diseases.

Based on end user, the mRNA synthesis and manufacturing market has been categorized into pharmaceutical and biotechnology companies, academic and research institutes, and CROs and CDMOs. In 2023, pharmaceutical and biotechnology companies dominated the market for mRNA synthesis and manufacturing. According to the market's emerging needs, companies are investing to develop next-generation biologics such as mRNA therapeutics. Higher research and development activities of companies to develop mRNA therapeutics and cell and gene therapies have resulted in rising needs for specialized consumables and instruments as well as synthesis, modification, purification, analysis, and characterization services.

Request Sample Pages:

The global mRNA synthesis and manufacturing market is consolidated with the top five players— Thermo Fisher Scientific Inc. (US), Aldevron, LLC. (Danaher Corporation) (US), TriLink BioTechnologies (US), GenScript (US), and Merck KGaA (Germany). Other prominent market players include, New England Biolabs (US), Promega Corporation (US), Sartorius AG (Germany), WuXi Biologics (China), Takara Bio Inc. (Japan), GENEWIZ (Azenta US, Inc.) (US), Lonza (Switzerland), Telesis Bio Inc. (US), Aurigene Pharmaceutical Services Ltd. (Dr. Reddy's Laboratories Ltd.) (India), ST Pharm (South Korea), AGC Biologics (US).

Thermo Fisher Scientific Inc. (US):

Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, is a leading player in mRNA synthesis and manufacturing, offering a broad range of products and services tailored to this field. The company provides advanced solutions for mRNA synthesis, including custom RNA synthesis services and reagents through its GeneArt platform, which supports the development of mRNA constructs for research, therapeutic, and vaccine applications. Thermo Fisher's technologies enable efficient in vitro transcription (IVT) and include automated solutions that enhance scalability and production efficiency. Their extensive expertise, quality assurance measures, and global reach position them as a key player in advancing mRNA technology and supporting the development of next-generation therapeutics and vaccines.

Aldevron, LLC. (Danaher Corporation) (US):

Aldevron, established in 1998 and based in Fargo, North Dakota, is a key player in the nucleic acid synthesis industry, particularly known for its expertise in mRNA synthesis and manufacturing. The company is highly regarded for producing high-quality mRNA and plasmid DNA, essential for cutting-edge applications in vaccine development, gene therapy, and other biotechnological innovations. Aldevron's offerings include custom RNA synthesis and cGMP-compliant mRNA production, ensuring that their products meet the stringent standards required for clinical use. Aldevron's robust quality control and assurance processes further guarantee the reliability and efficacy of their products. As a global leader in the field, Aldevron has expanded its facilities and technological infrastructure to meet growing demand, establishing a significant presence in the biopharmaceutical sector. Their collaborations with biotechnology firms, pharmaceutical companies, and research institutions underscore their pivotal role in advancing mRNA technology and supporting the development of next-generation therapies and vaccines.

TriLink BioTechnologies (US):

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences based in San Diego, California, is a key player in mRNA synthesis and manufacturing. The company excels in providing high-quality nucleic acid products and services, with a strong focus on mRNA technology. TriLink offers comprehensive mRNA synthesis services, including the production of custom mRNA and chemically modified mRNA, which enhances stability and translation efficiency—crucial for effective therapeutic and vaccine development. Utilizing advanced in vitro transcription technologies, TriLink ensures high yield and purity in their mRNA products.

For more information, Inquire Now!

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/

#mRNA Synthesis & Manufacturing Market

0 notes

rameshindustryarc · 15 days ago

Text

🌟 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: 𝐓𝐡𝐞 𝐑𝐢𝐬𝐞 𝐨𝐟 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐃𝐫𝐮𝐠 𝐂𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞𝐬 (𝐀𝐃𝐂𝐬) 🌟-IndustryARC™

The Antibody Drug Conjugate Market size is estimated to reach $15275 million by 2030, growing at a CAGR of 14.20% during the forecast period 2024-2030.

👉 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞

𝐇𝐞𝐫𝐞 𝐚𝐫𝐞 𝐬𝐨𝐦𝐞 𝐤𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭

𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐲: ADCs represent a targeted approach to cancer therapy, allowing for selective delivery of cytotoxic drugs to cancer cells, reducing damage to healthy cells and enhancing treatment effectiveness. This shift towards targeted therapies is a major trend in oncology.

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐨𝐟 𝐀𝐃𝐂𝐬: Pharmaceutical companies are actively developing ADCs, with a growing number of ADC candidates in clinical trials. Increased R&D investments and strategic collaborations are fueling the expansion of ADC pipelines, particularly for solid tumors and hematologic cancers.

𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐚𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐒𝐮𝐩𝐩𝐨𝐫𝐭: Regulatory bodies are accelerating approvals for ADCs due to their effectiveness and safety profile in cancer treatment. Recent approvals of ADCs, such as those targeting breast and bladder cancers, have driven further interest and investment.

𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐋𝐢𝐧𝐤𝐞𝐫 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: Innovations in linker technology, which attaches the antibody to the drug payload, are enhancing ADC stability and precision. Advanced linkers improve the therapeutic index, enabling more controlled drug release and minimizing off-target effects.

𝐅𝐨𝐜𝐮𝐬 𝐨𝐧 𝐍𝐨𝐯𝐞𝐥 𝐏𝐚𝐲𝐥𝐨𝐚𝐝𝐬: ADCs are moving beyond traditional cytotoxic agents, incorporating novel payloads such as immune modulators and DNA-damaging agents. These novel payloads expand ADC applications and offer enhanced potency against resistant cancer cells.

𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐢𝐧𝐭𝐨 𝐍𝐨𝐧-𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: While oncology remains the primary focus, ADCs are increasingly being explored for autoimmune and infectious diseases. This diversification presents new opportunities and broadens the market’s scope beyond cancer.

#antibodydrugconjugates #oncology #cancertherapy #targetedtherapy #precisionmedicine #cancerresearch #biotechnology #drugdevelopment #pharma #cancerimmunotherapy #biopharma #noveltherapeutics #tumortargeting #personalizedmedicine

0 notes

willyskristina · 25 days ago

Text

Mononucleosis Diagnostic Market

Mononucleosis Diagnostic Market Size, Share, Trends: Abbott Laboratories Lead

Integration of Artificial Intelligence and Machine Learning in Diagnostic Platforms

Market Overview:

The global Mononucleosis Diagnostic Market is projected to grow at a CAGR of 5.8% from 2024 to 2031. The market size is expected to reach XX in 2024 and YY by 2031. North America dominates the market, accounting for approximately 40% of the global market share. Key metrics include increasing incidence of Epstein-Barr virus infections, advancements in diagnostic technologies, and growing awareness about early disease detection.

The mononucleosis diagnostic market is steadily growing, owing to the increasing prevalence of infectious mononucleosis, particularly among teenagers and young adults. Demand for accurate and quick diagnostic tests is driving market growth, aided by technological advances in immunoassays and molecular diagnostics.

DOWNLOAD FREE SAMPLE

Market Trends:

The mononucleosis diagnostic market is undergoing a considerable change towards the integration of artificial intelligence (AI) and machine learning (ML) into diagnostic systems. This development is driven by the demand for higher accuracy, faster turnaround times, and better data interpretation in mononucleosis tests.

Recent research has yielded encouraging findings for AI-assisted diagnosis in infectious diseases. A pilot study of 500 mononucleosis cases found that using AI algorithms to analyze EBV antibody test results improved diagnostic accuracy by 20% compared to conventional approaches. Industry experts expect that by 2026, more than 30% of high-volume diagnostic laboratories will have integrated AI-powered technologies into their mononucleosis testing workflows, potentially lowering false-negative rates and enhancing overall diagnostic efficiency.

Market Segmentation:

The EBV Antibody Test segment dominates the mononucleosis diagnostic market, accounting for over 45% of the market share.

EBV antibody tests, which include VCA IgM, VCA IgG, and EBNA IgG antibodies, have established as the gold standard for accurately diagnosing mononucleosis. This segment's dominance is due to its high specificity and capacity to identify the stage of infection, which is critical for optimal patient care.

Market statistics supports the expansion of the EBV Antibody Test segment. A survey of 1,000 infectious disease doctors found that 80% choose EBV serology as the primary diagnostic method for probable mononucleosis cases. The segment is likely to maintain its dominance until 2031, driven by advances in multiplex serology platforms and the incorporation of automated interpretation algorithms.

Market Key Players:

Abbott Laboratories

Beckman Coulter, Inc. (Danaher Corporation)

Bio-Rad Laboratories, Inc.

DiaSorin S.p.A.

Meridian Bioscience, Inc.

Quidel Corporation

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market insights #market growth #market trends

0 notes

marketsndata · 2 months ago

Text

Global Gastrointestinal Drugs Market Size, Share, Growth and Forecast 2031

Global gastrointestinal drugs market is projected to witness a CAGR of 4.23% during the forecast period 2024-2031, growing from USD 45.20 billion in 2023 to USD 62.96 billion in 2031. The market’s growth is boosted by the rising cases of gastrointestinal diseases, novel product launches by the market players, and increasing emphasis on ensuring the availability of gastrointestinal drugs in different regions across the globe.

Technological advancements in drug delivery mechanisms and formulations are enhancing the efficacy of gastrointestinal drugs. The advancements include the development of extended-release and delayed-release formulations that aid in improving the bioavailability and absorption of the drugs, resulting in improved patient outcomes. Such developments are revolutionizing the treatment of ulcerative colitis and Crohn’s disease, among others, providing lucrative growth opportunities for the market.

The rising prevalence of various gastrointestinal disorders, such as celiac disease, is also propelling the growth of the global gastrointestinal drugs market. According to an article published in the StatPearls journal of StatPearls Publishing LLC in August 2023, the prevalence of celiac disease is approximately 0.5% to 1% among the general population. Additionally, the number of cases of Crohn’s disease is also increasing at a rapid rate. According to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, more than half a million people are suffering from Crohn’s disease in the United States. Thus, various pharmaceutical companies are investing in research activities to augment the development of novel therapies to combat the growing threat of Crohn’s disease. In October 2023, Eli Lilly and Company announced that the investigational interleukin-23p19 antagonist, mirikizumab met all major secondary and co-primary endpoints in a phase 3 study, evaluating its efficacy and safety for treating adults with severely to moderately active Crohn’s disease.

Increasing Cases of Gastrointestinal Diseases Boost Market Demand

The rising cases of gastrointestinal distress in various regions across the globe due to changes in lifestyle and eating habits of the population is one of the major factors bolstering the global gastrointestinal drugs market demand. Factors such as increased stress and the rising prevalence of obesity are also propelling the incidences of gastrointestinal diseases. According to the estimates of the World Health Organization (WHO), 1 in 8 people around the world were living with obesity in 2022. This increase is augmenting the incidences of diseases such as peptic ulcers, irritable bowel syndrome, and gastroesophageal reflux disease. Furthermore, the rapid expansion of the aging population is also boosting the demand for gastrointestinal drugs as the older population is more susceptible to gastrointestinal issues. The WHO estimates that approximately 1 in 6 people across the globe will be 60 or older by 2030. Due to the rising occurrences of such issues, pharmaceutical companies are also increasingly focusing on developing innovative therapies that address the underlying cause of the disease rather than alleviating symptoms.

Rising Efforts of Pharma Companies Supports Market Expansion

The rising efforts of the key players in the market to ensure the availability of novel gastrointestinal drugs through investments and partnerships is boosting the global gastrointestinal drugs market size. In June 2024, AbbVie Inc. secured its position in the gastrointestinal drugs market by paying USD 150 million to China-based FutureGen Biopharmaceutical (Beijing) Co., Ltd. in near-term fees for rights to antibody drug targeting TL1A molecule that has been linked with a heightened immune response in cases of inflammatory bowel disease.

Similarly, in June 2024, Akum Drugs and Pharmaceuticals Ltd. unveiled new formulations for gastrointestinal diseases for patients in India. The company’s Rabeprazole + Levosulpiride SR Capsules received approval from the Drug Controller General of India (DCGI). The drugs aim to provide relief to patients suffering from gastrointestinal tract disorders. Rabeprazole sodium, a potent antisecretory compound, has demonstrated efficacy in treating duodenal and gastric ulcers along with gastroesophageal reflux disease by selectively inhibiting the secretion of gastric acid. Such efforts are expected to aid patients suffering from gastrointestinal issues in effectively managing their conditions and provide lucrative growth opportunities to the gastrointestinal drug market.

Retail Pharmacies Hold Significant Market Share

The segment’s expansion can be attributed to the rising requirement for over-the-counter (OTC) gastrointestinal drugs over the past few years due to the rising cases of gastrointestinal distress and consumer preference for immediate relief from common digestive issues, including constipation, acid reflux, diarrhea, and heartburn. As per the American College of Gastroenterology (ACG) estimates, approximately 20% of the population of the United States suffers from gastroesophageal reflux disease. Due to the widespread presence of retail pharmacies and their convenient nature, patients suffering from gastrointestinal issues prefer them for purchasing medication, especially in semi-urban and urban locations.

Meanwhile, online pharmacies are expected to grow rapidly over the next few years due to the growing preference for online shopping, fast delivery, shipping, and the availability of lucrative discounts. Other advantages online pharmacies offer include increased consumer accessibility to a broad range of products. Additionally, the growing popularity of digital consultation and the rising availability of e-prescriptions have also made it easier for patients to avail themselves of the required medications through online pharmacies, bolstering the segment’s growth.

North America Holds Major Market Share

The growth of the North American gastrointestinal drugs market can be attributed to the increasing efforts of the leading market players based in the region to ensure novel product launches, rising cases of gastrointestinal diseases, and the presence of well-established healthcare and pharmaceutical sectors. Various gastrointestinal diseases, including ulcerative colitis, Crohn’s disease, and inflammatory bowel disease, are becoming increasingly prevalent in the United States, bolstering the market’s demand. As per the estimates of the US Centers for Disease Control and Prevention, the prevalence of inflammatory bowel disease is between 2.4 and 3.1 million in the United States, with differing burdens across groups. Additionally, the prominent presence of various research organizations that are increasingly focusing on investigating different gastrointestinal diseases is also expected to influence the market’s expansion positively. Moreover, the increasing availability of novel drugs due to the increasing provision of approvals by the regulatory bodies in the region is also supporting the market’s growth is the region. In 2023, the US Food and Drug Administration (FDA) provided approval to five new gastrointestinal targeted drugs, including colonoscopy prep, inflammatory bowel disease, and gastroesophageal reflux disease. Such approvals are expected to increase the influx of various gastrointestinal drugs in North America.

Download Free Sample Report

Future Market Scenario (2024-2031F)

As per the global gastrointestinal drugs market analysis, the market is expected to witness significant growth in the coming years due to the growing burden of different gastrointestinal diseases and the increasing efforts of the market players towards novel product launches. According to an article published in January 2024 in the Dovepress of the Dove Medical Press Ltd, the prevalence of Crohn’s disease is expected to increase to 1% in 2030 in Western European countries and the United States. This increase will bolster the market’s demand to meet the growing drug requirement for effective management and treatment of the condition. The cases of gastrointestinal distress are also expected to increase in the coming years due to the increasing preference for fast foods and dining out as a fast food-filled diet lacks essential fiber intake, resulting in decreased adoption of water.

Additionally, the market is also expected to witness significant growth over the forecast period due to the rising investments by the leading pharmaceutical companies towards research and development activities and the emphasis on creating targeted therapies that provide minimal side effects along with long-term relief. Furthermore, the growing efforts of various countries to enhance their healthcare sectors and ensure the availability of necessary therapies and treatment solutions are further expected to propel the global gastrointestinal drugs market growth.

Report Scope

“Gastrointestinal Drugs Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gastrointestinal drugs market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/gastrointestinal-drugs-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: [email protected] Website: https://www.marketsandata.com

#Gastrointestinal Drugs Market #Global Market #Market Research Reports #Market News

0 notes

delveinsight12 · 2 months ago

Text

MET Kinase Inhibitor Market: Size, Target Population, Competitive Landscape, and Forecast to 2034

The MET kinase inhibitor market represents a significant and rapidly advancing segment of cancer therapeutics, particularly in addressing malignancies driven by MET (mesenchymal-epithelial transition factor) signaling dysregulation. These inhibitors target the MET pathway, which is implicated in tumor growth, metastasis, and treatment resistance in various cancers. Here, we delve into the market dynamics, including its size, target population, competitive environment, and future outlook to 2034.

MET Kinase Inhibitor Market Size and Growth Drivers

The MET kinase inhibitor market is forecasted to experience substantial growth through 2034, driven by advancements in oncology research and the increasing prevalence of MET-driven cancers. MET pathway dysregulation is common in cancers like non-small cell lung cancer (NSCLC), gastric cancer, and papillary renal cell carcinoma, creating significant demand for targeted therapies.

The market is buoyed by:

- Expanding therapeutic applications: Beyond cancer, MET inhibitors are being explored for fibrotic and inflammatory diseases, which could broaden their market scope.

- Rising investments in oncology: Governments and private entities are boosting funding in cancer research, accelerating drug development and commercialization.

- Improved diagnostic capabilities: Advances in precision medicine enable better identification of MET-amplified or overexpressed tumors, facilitating targeted treatment.

North America and Europe are leading markets due to robust healthcare infrastructure and innovation hubs. Meanwhile, the Asia-Pacific region is poised for rapid growth, propelled by rising healthcare spending and increased cancer awareness.

Request for a sample page report @ https://www.delveinsight.com/sample-request/met-kinase-inhibitor-market-forecast

MET Kinase Inhibitor Target Population

The primary target population for MET kinase inhibitors includes patients with cancers harboring MET alterations:

- Non-Small Cell Lung Cancer (NSCLC): MET exon 14 skipping mutations and MET amplifications are significant targets in this subset of lung cancer patients.

- Gastric Cancer: MET overexpression is a critical factor in the pathogenesis of gastric and gastroesophageal cancers.

- Renal Cell Carcinoma: MET alterations drive tumor progression in some forms of kidney cancer.

Emerging evidence suggests potential applications in other cancers, including colorectal and breast cancer, expanding the addressable patient pool.

MET Kinase Inhibitor Competitive Landscape

The MET kinase inhibitor market is highly competitive, with both established pharmaceutical giants and innovative biotech companies actively participating. The competition is characterized by diverse therapeutic approaches, including small molecules and antibody-based inhibitors.

MET Kinase Inhibitor Key Players and Therapies

1. Novartis: The company's MET inhibitor, Capmatinib (Tabrecta), is approved for MET exon 14 skipping-mutated NSCLC, setting a benchmark for others in the field.

2. Merck KGaA: Tepotinib (Tepmetko) has shown significant efficacy in treating MET-altered NSCLC, particularly in Asian markets.

3. Eli Lilly: Lilly is actively exploring the potential of MET inhibitors as part of its oncology portfolio.

4. Emerging Biotechs: Several smaller firms are developing novel MET inhibitors, including bispecific antibodies that simultaneously target MET and other pathways to overcome resistance mechanisms.

MET Kinase Inhibitor Pipeline Developments

Over 20 candidates are in various stages of development, reflecting a rich pipeline. Research is focused on improving specificity, reducing toxicity, and exploring combination therapies with immune checkpoint inhibitors and other agents.

MET Kinase Inhibitor Technological Innovations

Innovation is pivotal to the MET inhibitor market. Key advancements include:

- Combination Therapy: Co-targeting MET and other pathways, such as EGFR or ALK, to enhance efficacy and overcome resistance.

- Biomarker-Driven Approaches: Precision diagnostics are integral to identifying suitable patients, ensuring higher therapeutic success.

- Optimized Delivery Systems: Improving oral bioavailability and reducing side effects are priorities in new formulations.

Download sample report @ https://www.delveinsight.com/sample-request/met-kinase-inhibitor-market-forecast

MET Kinase Inhibitor Market Challenges

Despite its promising trajectory, the MET kinase inhibitor market faces challenges:

1. Resistance Development: Tumors often develop resistance to MET inhibitors, necessitating new-generation therapies.

2. High Costs: Expensive R&D processes and drug pricing limit accessibility, particularly in emerging markets.

3. Regulatory Hurdles: The stringent regulatory environment requires extensive clinical data for approval, prolonging time-to-market.

These challenges are being addressed through collaborative R&D, cost-sharing models, and regulatory streamlining.

MET Kinase Inhibitor Forecast to 2034

The MET kinase inhibitor market is projected to achieve multi-billion-dollar revenues by 2034, with a robust CAGR. Growth will be driven by:

- Expanded Indications: Beyond oncology, research into MET inhibitors for fibrosis and inflammatory diseases could open new markets.

- Global Access: Initiatives to improve drug affordability and access in low- and middle-income countries will play a key role in market expansion.

- Technological Advancements: Continued innovation in drug delivery and biomarker-driven treatments will enhance adoption.

North America and Europe will maintain leadership in market share, while Asia-Pacific emerges as a key growth region due to rising healthcare infrastructure and patient awareness.

The MET kinase inhibitor market represents a dynamic and transformative segment in precision oncology. With ongoing advancements in diagnostics, therapeutic efficacy, and broader clinical applications, MET inhibitors hold immense potential to redefine cancer treatment paradigms. Stakeholders—including pharmaceutical companies, healthcare providers, and policymakers—must navigate challenges while seizing opportunities to capitalize on this promising market.

For a comprehensive analysis, including detailed market forecasts and emerging trends, refer to the [DelveInsight MET Kinase Inhibitor Market Report](https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast).

0 notes

palashbhagat5 · 1 day ago

Text

0 notes

imirmarketresearch · 2 months ago

Text

#Immunohistochemistry Market Size

0 notes

credenceresearchdotblog · 1 month ago

Text

The Radiotherapy-Induced Oral Mucositis Treatment Market is expected to grow from USD 1,122.25 million in 2024 to USD 1,535.87 million by 2032, at a CAGR of 4%. Radiotherapy-induced oral mucositis (RIOM) is a debilitating condition commonly experienced by cancer patients undergoing head and neck radiotherapy. Characterized by painful inflammation and ulceration of the oral mucosa, RIOM can significantly impact a patient's quality of life, nutritional intake, and treatment adherence. The growing prevalence of cancer and advancements in cancer therapies have heightened the need for effective treatment options, fueling the growth of the radiotherapy-induced oral mucositis treatment market.

Browse the full report at https://www.credenceresearch.com/report/radiotherapy-induced-oral-mucositis-treatment-market

Market Overview The global RIOM treatment market has witnessed steady growth over the past decade, driven by the increasing global incidence of cancer and the growing adoption of radiotherapy. According to the World Health Organization (WHO), head and neck cancers account for approximately 4–5% of all cancers worldwide, with a significant proportion of patients developing oral mucositis as a side effect of radiotherapy. This has created a substantial demand for innovative therapies aimed at managing and alleviating the symptoms of RIOM.

Key Treatment Modalities The treatment landscape for RIOM is diverse, encompassing various pharmacological and non-pharmacological approaches:

Pharmacological Interventions

Growth Factors and Cytokines: Palifermin (a keratinocyte growth factor) is a widely used treatment that promotes the repair of damaged oral tissues.

Anti-inflammatory Agents: These drugs, including corticosteroids, help reduce inflammation and pain.

Analgesics: Both systemic and topical painkillers are employed to manage the intense pain associated with RIOM.

Mouth Rinses and Coating Agents

Medicinal mouthwashes containing chlorhexidine, benzydamine, and antimicrobial agents play a critical role in maintaining oral hygiene and preventing secondary infections.

Protective coating agents like sucralfate form a barrier over ulcerated tissues, offering relief and promoting healing.

Emerging Therapies

Low-Level Laser Therapy (LLLT): LLLT has gained traction as a non-invasive treatment option, demonstrating effectiveness in reducing pain and accelerating tissue repair.

Biologics: Ongoing research in biologic drugs, including monoclonal antibodies, offers promising prospects for targeted treatment.

Nutritional and Supportive Care Adequate hydration, nutritional supplements, and diet modifications are integral to managing the condition.

Market Drivers Several factors are propelling the growth of the RIOM treatment market:

Increasing Cancer Prevalence The rising incidence of cancer globally, especially head and neck cancers, is a primary driver of market growth.

Advancements in Treatment Modalities Technological progress in radiation oncology, combined with innovations in supportive care therapies, has broadened the scope for effective RIOM management.

Rising Awareness and Accessibility Educational initiatives aimed at healthcare professionals and patients are fostering awareness about early intervention, driving demand for effective treatment solutions.

Regulatory Approvals and R&D Investments Regulatory approvals of novel therapies and increasing investments in clinical research are bolstering market expansion.

Challenges in the Market Despite its growth prospects, the RIOM treatment market faces several challenges:

High Cost of Advanced Therapies Treatments like biologics and LLLT are often expensive, limiting accessibility in low- and middle-income countries.

Limited Awareness in Developing Regions Inadequate knowledge about RIOM and its treatment options in underdeveloped regions hampers market penetration.

Side Effects of Treatments Some pharmacological treatments are associated with adverse effects, affecting patient compliance.

Future Outlook The RIOM treatment market is poised for significant advancements in the coming years. Key trends include:

Personalized Medicine: The integration of genomics and precision medicine into RIOM management is expected to revolutionize treatment outcomes.

Innovative Delivery Mechanisms: Research on nanotechnology-based drug delivery systems aims to enhance therapeutic efficacy and reduce side effects.

Expanding Applications of LLLT: As clinical evidence supporting LLLT grows, its adoption is likely to increase across healthcare facilities globally.

Key Player Analysis

Amgen Inc.

Aurora BioScience

Colgate-Palmolive Company

Galera Therapeutics

Enzychem Lifesciences Corporation

EpicentRx

Izun Pharmaceuticals

MuReva Phototherapy Inc.

Solasia Pharma K.K.

Soligenix Inc.

Segments:

Based on Drug Class:

Antibiotics

Antifungal

Anti-Inflammatory

Anti-Neoplastic

Based on Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Based on End User:

Hospitals

Oncology Centres

Research Institutes

Dental Clinics

Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/radiotherapy-induced-oral-mucositis-treatment-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

0 notes

healthcaremarketanalysis · 29 days ago

Text

mRNA Synthesis & Manufacturing Market worth $738.3 million by 2029

Download PDF Brochure:

Browse in-depth TOC on "mRNA Synthesis & Manufacturing Market"

250 - Tables

50 - Figures

250 - Pages

Request Sample Pages:

Thermo Fisher Scientific Inc. (US):

Aldevron, LLC. (Danaher Corporation) (US):

TriLink BioTechnologies (US):

For more information, Inquire Now!

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets Inc.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA : 1-888-600-6441

UK +44-800-368-9399

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/

#mRNA Synthesis & Manufacturing Market

0 notes

market-insider · 2 months ago

Text

Lyme Disease Testing Market Trends and Analysis: Comprehensive Overview of Market Size, Share, Growth

The global lyme disease testing market size is anticipated to reach USD 18.57 billion by 2030 and is projected to grow at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing prevalence, supportive government policies regarding healthcare facilities, and the introduction of new diagnostic tests for Lyme disease. In addition, the growing incidence of tick-borne diseases further expands the global market. For instance, in August 2022, the U.S. Fair Health Organization reported that Lyme disease has significantly increased in prevalence over the past 15 years, becoming a growing national concern.

Lyme Disease Testing Market Report Highlights

Based on technology, the other segment led the market with the largest revenue share of 88.6% in 2023. The widespread adoption of these tests, considered the gold standard for testing due to their high specificity and sensitivity, significantly contributed to the growth of this segment

Based on testing, the serological test segment led the market with the largest revenue share of 53.1% in 2023. These tests dominated the market as they are widely available, affordable, established, and reliable in detecting antibodies against Borrelia burgdorferi. This makes them a trusted and accessible option for healthcare providers and patients

Based on sample, the blood segment led the market with the largest revenue share of 62.4% in 2023. This is due to the blood tests, such as ELISA and Western blot, which can effectively detect antibodies against Borrelia burgdorferi, the bacteria causing Lyme disease. Blood samples are also easy to obtain and handle, making them a practical choice for widespread diagnostic use

Based on end use, the hospital segment led the market with the largest revenue share of 58.4% in 2023. Firstly, hospitals can access advanced technology and diagnostic tools, enabling accurate & timely testing. The high hospital patient volume, including those with complex and severe symptoms, necessitates reliable diagnostic services, further driving their market dominance

In January 2024, DiaSorin announced that it submitted the LIAISON LymeDetect test to the U.S. FDA in December 2023. Developed in partnership with QIAGEN, this test detects IgG, IgM, and T-cell mediated responses using QIAGEN’s proprietary QuantiFERON technology, an Interferon-Gamma Release Assay (IGRA). This novel solution will enhance DiaSorin's LIAISON immunodiagnostic offerings in the U.S. market, representing a significant milestone in its collaboration with QIAGEN

For More Details or Sample Copy please visit link @: Lyme Disease Testing Market Report

Growing government initiatives and preventive measures significantly drive the market growth. For instance, in July 2022, an article titled "New laws seek to boost funding of Lyme disease research" highlighted that New York officials have increased funding for Lyme disease and tick-borne illnesses through a new law signed by Governor Kathy Hochul. This bipartisan measure will establish a voluntary tax check-off box to support education, research, and prevention efforts related to the disease in the region. Despite the high incidence of Lyme and tick-borne illnesses, it is believed that the actual number of cases is much higher due to inaccurate diagnostic testing.

Heightened awareness and education are further propelling market growth. Public health campaigns to educate communities about prevention strategies and symptoms have become increasingly prevalent. This growing awareness leads to more individuals seeking medical attention when they exhibit symptoms consistent with the disease, thereby driving demand for reliable testing options. Furthermore, educational initiatives targeting healthcare professionals ensure they remain informed about best practices for diagnosis and treatment.

List of major companies in the Lyme Disease Testing Market

DiaSorin S.p.A

BIOMÉRIEUX

Oxford Immunotec

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific, Inc.

T2 Biosystems

IGeneX

Gold Standard Diagnostics

ZEUS Scientific

Trinity Biotech

For Customized reports or Special Pricing please visit @: Lyme Disease Testing Market Analysis Report

We have segmented global lyme disease testing market report based on technology, testing, sample, end-use, and region.

#LymeDisease #LymeDiseaseTesting #DiagnosticTesting #InfectiousDisease #HealthDiagnostics #MedicalTesting #VectorBorneDiseases #TickBorneIllness #LymeDiseaseDiagnosis #SerologyTests #PCRTesting #LymeDiseaseAwareness #PointOfCareTesting #LaboratoryDiagnostics #HealthcareMarket #MedicalDevices #ImmunoassayTests #DiagnosticsMarket

0 notes

marketanalysisdata · 2 months ago

Text

Squalene Industry - Technologies, Applications, Verticals, Strategies & Forecast 2030

The global squalene market was valued at USD 149.4 million in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2030. The increasing use of natural ingredients in personal care and cosmetic products is a primary driver behind this growth. Squalene, a natural organic compound, is highly valued in these industries due to its translucency, minimal odor, and strong moisturizing properties. These characteristics make it one of the most widely used emollients in skincare. Moreover, squalene’s non-toxic nature has further expanded its applications, making it ideal for use in various personal care products. In cosmetics, squalene oil is especially valued for its role in combating free radicals that damage skin cells and accelerate aging.

The European Union has banned shark oil-based products in cosmetics, which has pushed manufacturers to seek plant-based and synthetic alternatives for squalene production. Concern over shark population decline and the environmental impact of harvesting shark oil has led to increased demand for plant-derived squalene, primarily extracted from sources like olive oil, rice bran, and amaranth oil. Currently, about 65% of the world’s olive oil is produced, consumed, and exported within the European Union, making it a key region for squalene derived from plant-based oils.

Squalene-based adjuvants have been used in influenza vaccines for over 20 years due to their capacity to improve immune response, boost antibody production, and allow for lower doses of the main antigen. This ingredient has been widely recognized for its role in health emergencies, such as influenza outbreaks, due to its effectiveness as an immune enhancer. The COVID-19 pandemic further underscored its utility, as animal-derived squalene was included in COVID-19 vaccines for its immunity-boosting properties. Companies like GlaxoSmithKline (GSK) have established partnerships with other firms, including Sanofi S.A. and CureVac N.V., to facilitate the use of squalene in vaccine production.

Gather more insights about the market drivers, restrains and growth of the Squalene Market

Regional Insights:

Asia Pacific Squalene Market Trends:

Asia Pacific is anticipated to witness significant market growth due to the region’s access to raw materials, lower labor costs, reduced manufacturing costs, and the expansion of industries such as personal care, cosmetics, pharmaceuticals, nutraceuticals, and food and beverages. Countries like India, China, and Japan, which are abundant in raw materials like shark liver oil and olive oil, are emerging as leading producers of squalene for the market.

Europe Squalene Market Trends:

Europe led the squalene market in 2023 with a revenue share exceeding 32.8%, followed closely by the Asia Pacific region. The high share of the European market is largely due to the extensive production of olive oil, which is a primary plant-based source of squalene. Demand for squalene in Europe is particularly high in key economies like Germany, France, the UK, Italy, and Spain. Among European nations, Spain holds a significant portion of the region’s olive groves, which positions it as a major supplier for plant-based squalene. Consequently, European squalene manufacturers are shifting away from shark-based squalene toward plant-based sources.

France

In France, the pharmaceutical industry is notably influential in this market shift. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the pharmaceutical sector in France had one of the largest R&D budgets in 2021, with R&D spending representing 9.8% of total pharmaceutical revenue. Pharmaceutical companies in France are increasingly investing in research and development focused on creating eco-friendly medicines that utilize bio-based ingredients, a trend that is expected to increase the demand for plant-based squalene in the country’s pharmaceutical industry over the forecast period.

Germany

Germany also demonstrates strong demand for plant-based squalene. In 2020, the country imported approximately 85 tons of olive oil, driven by rising health-consciousness among consumers and the preference for plant-derived ingredients across various sectors. Major companies like L’Oréal in Germany have transitioned from animal-based to plant-based squalene in their formulations, aligning with consumer demand for sustainable and eco-friendly products.

Browse through Grand View Research's Category Food Additives & Nutricosmetics Industry Research Reports.

The global glutamic acid market size was valued at USD 12.55 billion in 2024 and is projected to grow at a CAGR of 8.6% from 2025 to 2030.

The global stearic acid market size was valued at USD 11.24 billion in 2023 and is projected to grow at a CAGR of 5.2% from 2024 to 2030.

Key Companies & Market Share Insights:

The squalene market is highly fragmented and competitive, with major players concentrated in Europe and North America. However, numerous smaller players operate in the Asia Pacific region, where they benefit from proximity to raw materials, particularly shark liver oil and olive oil, which are essential for squalene production.

To extend their reach, major players are adopting partnership strategies. By collaborating with companies in different regions, they can leverage established networks to distribute their products more broadly. For example, in May 2023, Amyris announced a partnership with Croda International Plc. This collaboration aims to supply pharmaceutical-grade squalene for use in vaccine adjuvants, enhancing immune response. Such partnerships demonstrate the strategic moves by leading companies to expand their market presence while meeting the growing demand for high-quality squalene in various applications, from personal care to pharmaceuticals.

Key Squalene Companies:

Amyris, Inc.

Sophim SAS

Henry Lamotte Oils GmbH

efpbiotek

Vestan Limited

Kuraray Co., Ltd.

Croda International Plc

AASHA BIOCHEM

Arbee

Oleicfat, s.l.

Kishimoto Special Liver Oil Co., Ltd.

Order a free sample PDF of the Squalene Market Intelligence Study, published by Grand View Research.

#Squalene Market Analysis #Squalene Market Trends #Squalene Market Growth #Squalene Industry Forecast

0 notes